Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncophage in resectable renal cell carcinoma
NCT01147536Phase 2Terminated
- Sponsor
- Agenus Inc.
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in renal cell carcinoma (RCC) comparing HSPPC-96 Vaccine with Placebo Extension (2 arms). Primary endpoint: Number of Participants With Positive Immunological Response Using Enzyme Linked Immunosorbent Assay (ELISPOT) Assay at Week 14. Started Jan 2010; status: terminated.
02
Drugs
vitespen
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01147536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147536.